Dementia with Lewy Bodies Consortium
The purpose of this study is to collect clinical information, brain imaging scans, and biological samples from people that have dementia with Lewy bodies. This information will help researchers improve the diagnosis, care, and treatment of patients with this disease.
Mitochondrial PET Imaging in Parkinson’s disease and Dementia with Lewy Bodies
The purpose of this study is to test whether a new brain imaging (PET scan) agent can detect the earliest changes in the brain of those with Dementia with Lewy Bodies or Parkinson’s disease. The overall goal is to develop a method that would allow us to monitor effects of new therapies that might slow or reverse the neurodegeneration of these diseases, and to detect the disease at its earliest initiation in brain cells, when therapies could better stop or slow the progression of disease.
Study Visits: 2 or 3 visits
- Age 40-85
- Recruiting those with a diagnosis of Lewy Body Disease, Parkinson’s disease, Parkinson’s disease dementia, and also recruiting control participants with no neurologic diagnosis or cognitive impairment
- Not on blood thinners and no contraindications for MRI
Patricia McGeown at 412-692-2722 or mcgepg@UPMC.EDU
Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)
The study is designed to examine the efficacy and safety of escitalopram in combination with a psychosocial intervention (PSI) as treatment for agitation in AD patients.
Alzheimer’s Disease Neuroimaging Initiative – 3 (ADNI3)
The overall goal is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD) from its earliest stages. Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection. For more information about the ADNI3 study visit:
Study Length: up to 5 years
- 55-90 years of age
- Cognitively normal; or have Mild Cognitive Impairment (MCI); or have been diagnosed with Alzheimer’s disease
- A study partner who will accompany you to all study visits
MaryAnn Oakley at 412-692-2721 or email@example.com
Lithium As a Treatment to prevent Impairment of Cognition in Elders (LATTICE)
The purpose of this study is to examine the potential disease modifying properties of lithium in individuals with mild cognitive impairment (MCI). For additional information visit:
Connectomes in Brain Aging
This study will determine how different parts of the brain are connected and how these connections allow people to think, behave and feel. The study will involve 2-3 days of scanning and tests. Some people will be asked to return after two years.
Study Length: 2-3 days and for some two years
- 50-89 years of age
- Cognitively normal; or have Mild Cognitive Impairment (MCI); or have been diagnosed with Alzheimer’s disease.
MaryAnn Oakley at 412-692-2721 or firstname.lastname@example.org or
Rebecca Roush 412-586-9860
Senior Moments Study
The University of Pittsburgh Alzheimer’s Disease Research Center needs your help to better understand how mild memory changes may or may not relate to the future development of Alzheimer’s disease.
FORAging – Facilitating Optimal Routines in Aging
This study is looking at ways to minimize problems with everyday tasks by using a new strategy.